Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma | Zendy

Ghassan K. AbouAlfa | Zendy; Tim Meyer | Zendy; AnnLii Cheng | Zendy; Anthony B. El-Khoueiry | Zendy; Lorenza Rimassa | Zendy; BaekYeol Ryoo | Zendy; İrfan Çiçin | Zendy; Philippe Merle | Zendy; Yen-Hsun Chen | Zendy; JoongWon Park | Zendy; Jean-Frederic Blanc | Zendy; Luigi Bolondi | Zendy; HeinzJosef Klümpen | Zendy; Stephen L. Chan | Zendy; Vittorina Zagonel | Zendy; Tiziana Pressiani | Zendy; Min-Hee Ryu | Zendy; Alan P. Venook | Zendy; Colin Hessel | Zendy; Anne E. Borgman-Hagey | Zendy; Gisela Schwab | Zendy; Robin Kate Kelley | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma

Author(s) -

Ghassan K. AbouAlfa,

Tim Meyer,

AnnLii Cheng,

Anthony B. El-Khoueiry,

Lorenza Rimassa,

BaekYeol Ryoo,

İrfan Çiçin,

Philippe Merle,

Yen-Hsun Chen,

JoongWon Park,

Jean-Frederic Blanc,

Luigi Bolondi,

HeinzJosef Klümpen,

Stephen L. Chan,

Vittorina Zagonel,

Tiziana Pressiani,

Min-Hee Ryu,

Alan P. Venook,

Colin Hessel,

Anne E. Borgman-Hagey,

Gisela Schwab,

Robin Kate Kelley

Publication year - 2018

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa1717002

Subject(s) - cabozantinib , sorafenib , hepatocellular carcinoma , medicine , oncology , tyrosine kinase inhibitor , carcinoma , vascular endothelial growth factor , tyrosine kinase , placebo , cancer research , vegf receptors , receptor , pathology , cancer , alternative medicine

Cabozantinib inhibits tyrosine kinases, including vascular endothelial growth factor receptors 1, 2, and 3, MET, and AXL, which are implicated in the progression of hepatocellular carcinoma and the development of resistance to sorafenib, the standard initial treatment for advanced disease. This randomized, double-blind, phase 3 trial evaluated cabozantinib as compared with placebo in previously treated patients with advanced hepatocellular carcinoma.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research